Medicare Price Negotiation, Generic Availability, and Out-of-Pocket Costs for Cardiac Medications - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Medicare Drug Price Negotiations, Generic Access, and Patient Costs for Cardiovascular Medications

  • By

  • Celeste W. Franklin

  • Nathalia Ladino

  • Neha Parvathala

  • Gary C. N. Hettinger

  • Harmony R. Reynolds

  • Samrachana Adhikari

  • Saul Blecker

  • Amrita Mukhopadhyay

  • November 19, 2026

Share

Objective:

To assess how Medicare price negotiation was associated with 30-day out-of-pocket costs for high-cost cardiovascular medications and whether generic availability affected the association.

Approach:
  • Design and data: Repeated cross-sectional, plan-level analysis of Medicare drug coverage data before and after negotiation implementation, using a difference-in-differences approach.
  • Medications and analysis: Compared medications selected for negotiation with nonselected cardiovascular medications. Separate models examined medications with and without newly available generic alternatives; confidence intervals used plan-level cluster bootstrapping.
Key Findings:
  • The analysis included 6,215 Medicare drug coverage plans: 5,738 Medicare Advantage and 477 stand-alone plans.
  • Negotiation was associated with a $56.63 decrease in 30-day out-of-pocket costs for medications without a generic option (95% CI, $55.48-$57.78).
  • For medications for which a generic became available, the associated decrease was $7.46 (95% CI, $6.05-$8.78).
Interpretation:

The authors reported that generic availability appeared to attenuate the association between price negotiation and lower out-of-pocket costs. They identified the timing of drug selection and negotiation as a potential missed opportunity.

Limitations:
  • The study covered only the first year of negotiation, a short period, and a small number of cardiovascular medications.
  • Costs reflected 30 days in the initial coverage phase and did not account for other contemporaneous policy changes.
  • Plan-level data did not include beneficiary enrollment, diagnoses, individual costs, other barriers, or clinical outcomes.
Conclusion:

The study found lower 30-day out-of-pocket costs associated with Medicare price negotiation, with a considerably smaller reduction for medications with newly available generic alternatives.

Original Source(s)

Related Content